Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9123696 | 0.86 | TAAR1 (0.41) | TAAR1CYP1A2CYP2A6AMY1AALDH1A1 | |
| SCHEMBL8142729 | 0.86 | AMY1A (0.38) | TAAR1CYP1A2CYP2A6AMY1AHTR2B | |
| SCHEMBL9122973 | 0.83 | TAAR1 (0.38) | TAAR1CYP1A2CYP2A6AMY1AALDH1A1 | |
| SCHEMBL1721087 | 0.82 | ALDH1A1 (0.46) | TAAR1CYP1A2CYP2A6ALDH1A1KDM4E | |
| SCHEMBL29783360 | 0.82 | ALDH1A1 (0.46) | TAAR1CYP1A2CYP2A6ALDH1A1KDM4E | |
| SCHEMBL1050239 | 0.82 | TAAR1 (0.56) | TAAR1CYP1A2CYP2A6AMY1AALDH1A1 | |
| SCHEMBL3772270 | 0.80 | HTR2A (0.41) | TAAR1CYP1A2CYP2A6ALDH1A1HTR2A | |
| SCHEMBL30806439 | 0.80 | TAAR1 (0.39) | TAAR1CYP1A2CYP2A6AMY1AALDH1A1 | |
| SCHEMBL30558293 | 0.80 | HTR2A (0.41) | TAAR1CYP1A2CYP2A6ALDH1A1HTR2A | |
| SCHEMBL2291344 | 0.80 | TAAR1 (0.39) | TAAR1CYP1A2CYP2A6AMY1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686204-A1 | THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| EP-3192787-A1 | METHOD FOR PRODUCING FULLERENE DERIVATIVE | Showa Denko K.K. (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20170197977-A9 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| WO-2016090079-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378473-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120004476-A1 | Fullerene Derivatives and Organic Electronic Device Comprising the Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-05 | — | — | US | disclosed |
| EP-2392555-A2 | FULLERENE DERIVATIVES AND ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME | Korea Research Institute of Chemical Technology (KRICT) (KR) | 2011-12-07 | — | — | EP | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010087655-A2 | FULLERENE DERIVATIVES AND ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME | 한국화학연구원 (KR) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010087655-A2 | FULLERENE DERIVATIVES AND ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME | 한국화학연구원 (KR) | 2010-08-05 | — | — | WO | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1361219-A1 | Herbicidal indanylalkylamino-1,3,5-triazines, process for their preparation, compositions thereof, and their use as herbicides and plant growth regulators | Bayer CropScience GmbH (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-5698580-A | TREATING DISEASES CAUSED BY RESPIRATORY SYNCYTIAL VIRUS | RATIONAL DRUG DESIGN LABORATORIES (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0770609-A1 | ANTIVIRAL AGENT CONTAINING BENZODITHIIN DERIVATIVE AS ACTIVE INGREDIENT | Rational Drug Design Laboratories (JP) | 1997-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | TAAR1 125/4885CYP1A2 3215/4885CYP2A6 4151/4885 |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | TAAR1 224/4885CYP1A2 3046/4885CYP2A6 791/4885 |
| US-20140378473-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, CHRNB2 | TAAR1 74/4885CYP1A2 2700/4885CYP2A6 3898/4885 |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | TAAR1 3031/4885CYP1A2 4214/4885CYP2A6 3968/4885 |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | TAAR1 125/4885CYP1A2 3215/4885CYP2A6 4151/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | TAAR1 2120/4885CYP1A2 873/4885CYP2A6 838/4885 |
| US-20170197977-A9 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, CHRNB2 | TAAR1 74/4885CYP1A2 2700/4885CYP2A6 3898/4885 |
| US-20120004476-A1 | Fullerene Derivatives and Organic Electronic Device Comprising the Same | SCO2, VDAC2, TRPA1 | TAAR1 4442/4885CYP1A2 465/4885CYP2A6 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.